Welcome to our dedicated page for Windtree Therapeutics SEC filings (Ticker: WINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with clinical trial data, milestone-based licensing clauses, and non-cash warrant valuations is challenging. Windtree Therapeutics’ disclosures add another layer—cardiogenic shock trial endpoints, KL4 surfactant production metrics, and intricate royalty waterfalls. If you have ever typed “What does Windtree Therapeutics report in their SEC filings?” only to scroll through hundreds of pages, this page was built for you.
Stock Titan’s AI reads every Windtree Therapeutics quarterly earnings report 10-Q filing and annual report 10-K simplified within minutes, then surfaces clear context—trial spend by program, remaining cash runway, and pending FDA milestones. Need Windtree Therapeutics insider trading Form 4 transactions? We stream Form 4 insider transactions real-time, flagging executive stock transactions Form 4 seconds after they reach EDGAR. Our engine also turns dense 8-K material events explained into concise briefs and clarifies what each proxy statement executive compensation line means for dilution and governance.
Whether you are comparing burn rates, tracking when istaroxime moves into Phase 3, or simply understanding Windtree Therapeutics SEC documents with AI, you will find every filing type here in one place. Real-time alerts, keyword search, and inline charts convert raw data into insight. Start with our overview card—Windtree Therapeutics SEC filings explained simply—and finish with a Windtree Therapeutics earnings report filing analysis that links numbers to clinical catalysts. In short, all the information you need, none of the friction.
Windtree Therapeutics (NASDAQ:WINT) filed an 8-K disclosing three material events dated June 24-25, 2025.
- $150,000 raised via two 14% convertible promissory notes (12-month maturity, $0.587 conversion price) plus warrants covering 75% of each investment.
- Seller TBB Crescent Park Drive LLC terminated a Texas real-estate purchase; it demands release of $3 million earnest money paid by Way Maker and Windtree, which the company is disputing.
- CFO Jamie McAndrew resigned effective June 25; CEO Jed Latkin will serve as interim principal financial officer.
The notes and warrants were issued under Rule 506(b) exemptions and proceeds will fund operations. The property dispute could create a cash outflow materially larger than the new financing, and management turnover raises governance concerns.
Windtree Therapeutics (WINT) has received a Nasdaq deficiency notice on June 18, 2025, for failing to maintain the minimum bid price requirement of $1.00 per share over the last 30 consecutive business days.
Unlike standard cases where companies receive a 180-day compliance period, Windtree faces immediate delisting risk due to two key factors:
- The company is under a Discretionary Panel Monitor until March 20, 2026
- It has conducted two reverse stock splits in the past two years with a cumulative ratio exceeding 250:1, making it ineligible for the standard compliance period
Windtree plans to request a hearing before the Nasdaq Hearings Panel by June 25, 2025, which will automatically stay any suspension/delisting action. The company's stock continues trading on Nasdaq Capital Market under "WINT" symbol, though there is no guarantee of maintaining the listing or regaining compliance.
FAQ
What is the current stock price of Windtree Therapeutics (WINT)?
What is the market cap of Windtree Therapeutics (WINT)?
What is the core focus of Windtree Therapeutics Inc?
What technologies does Windtree Therapeutics utilize?
Can you explain the significance of istaroxime in their pipeline?
How does Windtree Therapeutics support its clinical development efforts?
What role does intellectual property play in their strategy?
How does the licensing model benefit Windtree Therapeutics?
How is Windtree addressing current market needs in the biotechnology sector?
What differentiates Windtree Therapeutics from its competitors?
